The pain ranks among the worst of any skin disease, and the mental-health burden β roughly one in five patients with clinical depression, suicide risk elevated β is among the heaviest in dermatology. Modern injectable medicines substantially shrink that whole stack; about 40 to 60 percent of patients hit a meaningful response by the four-month mark. The catch is access, not effectiveness: U.S. list prices are five-figure, copay programs usually make it manageable for insured patients, and the bigger barrier is just finding a dermatologist who recognises HS in the first place.
For decades the textbook story was "infected sweat glands," which is wrong and helped delay the field. HS starts when hair follicles in fold-skin get plugged β for reasons rooted in genetics, smoking and weight, plus an immune system that runs hot in this tissue β and then rupture into the surrounding skin. The body attacks what spills out: keratin, normal skin bacteria, cell debris. Two signaling proteins do most of the damage: TNF (tumour necrosis factor) and the IL-17 family (interleukin-17). That's why the modern medicines work β each one blocks one of those signals.
Repeated rupture-and-attack cycles do something worse than just inflame. Two old lesions a centimetre apart connect under the skin into a draining tract that lines itself with surface cells. That tunnel is now permanent anatomy. Medicine can quiet the inflammation around an established tunnel, but it can't close the tunnel itself. That permanence is the central lesson of the disease.
What treatment actually does
Three injectable medicines have been approved for HS since 2015, and the response numbers from their large trials are similar across all three. The standard bar β called HiSCR50 β is at least a 50 percent reduction in the count of abscesses and inflamed nodules, with no increase in draining tunnels. About 40 to 60 percent of patients hit it by week 12 to 16 on adalimumab, secukinumab or bimekizumab. That's not remission; it's a meaningful reduction in the worst of the active disease, and it sits on top of pain scores that drop in parallel.
What no trial yet shows: that one biologic beats another head to head, or that catching disease early prevents the tunnel-and-scar trajectory better than late rescue. Both are mechanistically expected; neither is proven.
What everyone gets wrong
Three things, all damaging.
It's not a hygiene problem. The most scrupulously clean patient still flares. HS lesions usually grow either no bacteria at all or normal skin bacteria; the immune dysregulation runs the same regardless of how often the affected skin is washed.
It's not infected sweat glands. The older textbook model named the apocrine glands because the disease shows up where they live; it's the hair follicles that occlude and rupture. This isn't pedantic β the wrong model produces wrong treatment (endless short antibiotic courses aimed at killing bacteria rather than calming inflammation).
It usually doesn't burn out. The common reassurance that HS "goes away in your forties" is mostly wrong. Most patients carry active disease well into the fifth and sixth decade. Waiting it out is a losing strategy, because the tunnels and scarring laid down while you wait don't go anywhere.
What happens when nobody names it
Year one with HS, you assume it's an ingrown hair, then a stubborn boil. Year two, your GP gives you a week of antibiotics and the spot heals enough that you accept the diagnosis "recurrent boils." Year three, a surgeon drains an abscess in your groin under local anaesthetic; it returns three months later in the same spot. Year four, you stop showing your partner the marks. By year seven you've seen a GP, two dermatologists, a surgeon and a gynaecologist; you've collected three labelled diagnoses, all wrong (Saunte 2015).
The boils don't keep being boils. They tunnel. Two old lesions a centimetre apart connect into a draining tract that lines itself with skin cells and becomes permanent β quietable but not closable. By the time a dermatologist finally names hidradenitis suppurativa, an average of seven to ten years after the first nodule, the architecture under your skin is mostly built. You can stop the new lesions; you can't undo the old tunnels and the scarring left behind.
The rest of you has been tracking too. Roughly one in five people with HS is clinically depressed; in the most severe stage that climbs to about one in three. Suicide risk runs higher than baseline. Heart-attack and cardiovascular-death rates run sharply higher than baseline as well (Machado 2019; Egeberg 2016). The longer the inflammation runs unaddressed, the more weight that whole stack carries β and the version of midlife waiting on the other side gets quietly more expensive.
What treatment actually looks like
The ladder is stratified by severity, and modern guidelines push biologics earlier for moderate disease than the older convention allowed (Alikhan 2019b). It's a clinician's call, not a self-prescribe β but knowing the shape lets you ask the right questions when you finally reach the dermatologist.
Two practical realities. HS biologic doses are higher than the same drugs at psoriasis doses, and response is judged at week 12 to 16, not week 4. Patients and clinicians calibrated to faster-responding skin conditions sometimes quit too early.
When the biologics aren't safe
The general safety profile of these medicines is strong; the headline risks are predictable and screen-able. Your dermatologist will work through them before you start. The short list to have in mind:
Cost, access, and what it looks like in real life
Specialist access is the rate-limiting reality. The diagnosis is made by a dermatologist β often an HS-specialty clinic at an academic centre β and most generalists won't recognise it. First-appointment wait times in the U.S. and U.K. can stretch months.
The biologics are injected at home, weekly to every four weeks depending on the drug. U.S. list prices run roughly $50,000 to $70,000 a year. Adalimumab biosimilars have arrived and dropped real prices substantially. Manufacturer copay assistance programmes typically take a commercially insured patient's monthly out-of-pocket well under $100; Medicare and Medicaid coverage is variable, and insurers usually require step therapy (try antibiotics first) before approving a biologic. Outside the U.S., single-payer systems generally cover after conventional therapy fails.
Monitoring labs are modest: a tuberculosis screen and hepatitis serology before starting, then periodic blood counts and liver tests.
Where treatment goes wrong
The single biggest failure mode is the diagnostic delay itself β seven to ten years of misnamed disease, during which the under-skin architecture sets (Saunte 2015). Anyone who suspects HS should push toward a dermatology referral and, when possible, an HS-experienced clinic.
The second is endlessly repeating incision-and-drainage of new abscesses without ever instituting disease-modifying therapy. It feels productive β the pain comes down for a few weeks β but the trajectory doesn't change.
The third is under-dosing or quitting biologic therapy too early. HS doses are higher than the psoriasis doses on the same labels, and response is judged at week 12 to 16. Stopping at week 6 because nothing has obviously changed yet is the predictable mistake.
The fourth is treating the skin and ignoring the rest. HS is a systemic inflammatory disease, not a local one β screening for depression, cardiovascular risk and metabolic syndrome belongs in routine HS care, not as an afterthought (Egeberg 2016; Tzellos 2015).
What changes when you get treated
Weeks one to four on a biologic, not much visible yet β the trial data show separation from placebo starting around week 4 and growing from there. By week 8 the people closest to you start noticing fewer flares. By week 12 to 16, the standard trial endpoint, about half of patients hit a meaningful reduction in lesion count and pain; about a third on bimekizumab hit a 75 percent reduction (Kimball 2024). The "severe pain" share collapses β in the bimekizumab trials it dropped from roughly 30 percent of patients at baseline to about 5 percent by the one-year mark.
The downstream version is what people quietly start saying back. Your partner stops planning around your bad days. The friend who didn't know you'd been hiding it doesn't comment, because there's nothing visible to comment on. Old tunnels stay scarred but stop draining and stop hurting. Within months you've taken several things off the books at once: the twenty minutes a day of wound care, the nights you didn't really sleep because every position pressed on something tender, the evening of pain-fog that ate dinner, and the social withdrawal you'd quietly built around the bad weeks.
Over years, the trial extensions show responses largely hold for patients who stay on therapy. The deeper bet β that quieting the inflammation also lowers the cardiovascular and mortality risk the disease drags along β is biologically plausible and supported by signals in the registry data, but the hard-endpoint trials haven't been done yet.
Adjacent topics worth knowing about
Smoking cessation as a standalone topic β the single biggest modifiable risk factor for HS severity. Weight management and GLP-1 receptor agonists like semaglutide, which show early benefit on HS independent of their primary indications. Inflammatory bowel disease, which co-occurs with HS more than chance would explain and shares some of the same underlying biology. Dermatology access in general β the bottleneck on a lot of skin-disease outcomes, this one included.
- β Smoking is one of the strongest drivers of this disease β quitting is part of the treatment.
- β The injectable medicines that changed this disease are part of the same biologic revolution against inflammation.
- β The mental-health burden here is heavy β one in five with depression β so mood support is part of care.
- β HS and Crohn's travel together and respond to the same TNF biologics, so one diagnosis can change how the other is treated.
- β HS travels with insulin resistance and PCOS β the same hormonal, follicle-clogging biology. Worth screening for if your cycles are off too.
Substance and claimed effects
Hidradenitis suppurativa (HS), also called acne inversa, is a chronic relapsing inflammatory skin disease centred on hair-follicle units in intertriginous skin: axillae, groin, perianal/perineal area, buttocks, inframammary fold. Clinical hallmarks are recurrent painful inflammatory nodules and abscesses (Hurley stage I); recurrent abscesses with sinus tracts and scarring (stage II); and diffuse interconnected sinus tracts, draining tunnels and extensive scarring across an entire anatomic region (stage III) Sabat 2020. The condition is not contagious, not primarily infectious, and not a hygiene problem β it is a primary disorder of innate immune dysregulation around occluded hair follicles Wolk 2020.
Claimed effects this entry covers holistically: dermatologic disease control (lesion count, flare frequency, draining tunnels), pain, scarring trajectory and visible skin damage over years, mental-health comorbidity (depression, anxiety, suicidality), cardiometabolic comorbidity and all-cause mortality, sleep disruption from nocturnal pain, energy and focus cost from chronic inflammation and chronic pain, and the diagnostic-delay penalty of an average 7β10 years from symptom onset to diagnosis Saunte 2015. Modern medical management β long-course antibiotics, hormonal adjuncts, and TNF-Ξ± / IL-17 biologics (adalimumab, secukinumab, bimekizumab) β alongside selective surgery substantially changes every one of those trajectories Kimball 2016 Kimball 2023 Kimball 2024.
Evidence by addressing question
mechanism
Science / mechanism. The primary pathogenic event is follicular occlusion of the folliculopilosebaceous unit, not apocrine-gland infection (the discarded 20th-century model). Infundibular hyperkeratosis and follicular plugging precede follicular rupture; ruptured keratin, cellular debris and commensal flora spill into the perifollicular dermis and trigger an innate immune cascade dominated by IL-1Ξ², TNF-Ξ±, and the IL-17 / IL-23 / Th17 axis, with neutrophil-rich abscess formation and downstream draining sinus tracts that epithelialise and become permanent anatomical features Wolk 2020 Sabat 2020. Th17 dominance is the mechanistic rationale for IL-17A / IL-17A+F blockade (secukinumab, bimekizumab); TNF-Ξ± elevation is the rationale for adalimumab. Smoking and obesity are the dominant non-genetic risk modifiers β meta-analysis pooled OR ~3.10 for smoking and ~2.48 for obesity β likely through follicular and microbiomic effects rather than primary autoimmune triggering. Genetic contribution is real but heterogeneous: Ξ³-secretase complex mutations (NCSTN, PSEN1, PSENEN) explain a minority of familial cases; most disease is polygenic with strong gene-environment interaction.
Practice / clinical consensus. The shift from "infected sweat glands" to "follicular-occlusion immune disease" is now consensus across North American (USCHSF/CHSF) and European (EHSF, EuroGuiDerm) guideline bodies Alikhan 2019a. Antibiotic regimens (notably clindamycinβrifampicin) act partly as anti-inflammatories, not purely as antimicrobials β supporting the immune-disease model.
evidence
Adalimumab (TNF-Ξ± blockade). PIONEER I and II were twin Phase 3 placebo-controlled RCTs (n=633 combined) of weekly subcutaneous adalimumab 40 mg in moderate-to-severe HS. The primary endpoint, HiSCR (β₯50% reduction in abscess + inflammatory nodule count, no increase in abscess or draining-fistula counts) at week 12, was met: PIONEER I 41.8% vs 26.0% placebo; PIONEER II 58.9% vs 27.6% placebo Kimball 2016. This led to FDA approval in 2015 β the first ever approved systemic therapy for HS.
Secukinumab (IL-17A blockade). SUNSHINE and SUNRISE (nβ1,084 combined, 40 countries) tested secukinumab 300 mg subcutaneously every 2 weeks vs every 4 weeks vs placebo through week 16, with continuation to week 52. HiSCR at week 16 was met for the every-2-week arm in both trials (SUNSHINE 45% vs 34% placebo; SUNRISE 42% vs 31% placebo) with sustained or improved response at week 52 and a favourable safety profile Kimball 2023. FDA-approved for moderate-to-severe HS in October 2023.
Bimekizumab (IL-17A + IL-17F dual blockade). BE HEARD I and II (n=1,014 combined, 48 weeks) showed HiSCR50 at week 16 of ~48β52% with bimekizumab vs ~29β32% placebo, and HiSCR75 ~32β34% vs ~12β14% β the deepest responses yet demonstrated in HS RCTs, with rapid onset (significant separation by week 4) and durability through 48 weeks Kimball 2024. Pain responses were substantial: at week 48, 56β64% of patients rated their skin pain as "much better." FDA-approved May 2024.
Antibiotics. Clindamycin 300 mg twice daily + rifampicin 600 mg daily for 10β12 weeks remains a workhorse for moderate disease β supported by Gener's 116-patient retrospective series showing significant Sartorius-score improvement Gener 2009 and a 283-patient prospective European cohort showing comparable HiSCR (~48%) to tetracycline monotherapy Alikhan 2019b. The evidence base is heterogeneous (mostly retrospective, mixed Hurley severity) but the regimen sits in every modern guideline.
Surgery. Systematic review of 22 studies: pooled recurrence ~13% for wide local excision (best with flap or graft closure: 6β8%), ~22% for local excision, ~27% for deroofing β though deroofing is tissue-sparing and tracts within an anatomic region can be picked off individually Mehdizadeh 2015. Surgery does not cure HS β new lesions arise in previously unaffected skin β but for Hurley III disease, wide excision is often the only intervention that durably controls established tunnels.
Comorbidity-modifying evidence. Adalimumab reduced systemic inflammation markers in PIONEER follow-up analyses, plausibly translating to cardiovascular risk reduction β though hard-endpoint CV trials in HS do not yet exist. Bariatric weight loss β₯15% and GLP-1 receptor agonists (semaglutide, tirzepatide) show emerging benefit on HS severity in observational and small cohort studies JΓΈrgensen 2024.
protocol
Practice / clinical consensus. Treatment is stratified by Hurley stage and disease activity, per North American and European guidelines Alikhan 2019a Alikhan 2019b. Foundation layer (all stages): smoking cessation, weight optimisation if BMI elevated, topical clindamycin 1% solution for mild localised disease, intralesional triamcinolone (5β10 mg/mL) for acute painful nodules, daily chlorhexidine or antiseptic wash. Stage IβII active disease: oral tetracyclines (doxycycline 100 mg twice daily Γ 12 weeks) or clindamycin 300 mg twice daily + rifampicin 600 mg daily Γ 10β12 weeks; hormonal adjuncts in female patients (spironolactone 100β200 mg/day, combined OCP, metformin if insulin resistance). Stage IIβIII or treatment-refractory: biologic therapy. Adalimumab 160 mg week 0, 80 mg week 2, then 40 mg weekly maintenance Kimball 2016. Secukinumab 300 mg every 2 weeks after a loading schedule Kimball 2023. Bimekizumab 320 mg every 2 weeks for 16 weeks then every 4 weeks Kimball 2024. Surgical adjuncts (deroofing of focal tunnels, wide excision of tunnel networks) integrated alongside biologic therapy in Hurley III. Pain management with NSAIDs, neuropathic-pain adjuncts (gabapentin, duloxetine) for chronic-pain phenotype; opioid avoidance is the standard given long disease horizon.
contraindications
Practice. TNF-Ξ± and IL-17 biologic contraindications largely follow the labels validated in their primary indications (psoriasis, ankylosing spondylitis, IBD) Alikhan 2019b. Adalimumab: active serious infection including untreated latent tuberculosis (TB screening mandatory before initiation), moderate-to-severe heart failure (NYHA III/IV β adalimumab can worsen heart failure), demyelinating disease, active malignancy within 5 years (relative). IL-17 inhibitors (secukinumab, bimekizumab): active Candida infection (increased mucocutaneous candidiasis on therapy), active TB, inflammatory bowel disease (IL-17 blockade can paradoxically flare IBD β relative contraindication). Pregnancy: adalimumab has the largest reassuring safety dataset of the three and is the preferred biologic if therapy is needed during pregnancy; IL-17 inhibitors have less data and are typically held. Live vaccines contraindicated during therapy. Hepatitis B/C screening required before any biologic initiation. Clindamycinβrifampicin: rifampicin is a potent CYP3A4 inducer β major interactions with hormonal contraceptives (reduced efficacy β backup contraception required), warfarin, many antiretrovirals, tacrolimus, statins.
misconceptions
The most common and most damaging misconception β held by patients and generalist clinicians β is that HS lesions are infected sweat glands or boils caused by poor hygiene, sexual activity, or shaving practice. This drives the average 7β10 year diagnostic delay, repeated futile incision-and-drainage procedures, repeated short antibiotic courses for "recurrent furunculosis," and the corrosive patient shame that suppresses care-seeking Saunte 2015. The mechanism is follicular-occlusion immune disease, not infection (cultures are frequently sterile or grow commensals) and not a hygiene failure (the most fastidious patients still flare) Wolk 2020. Second misconception: that HS is a self-limiting condition that "burns out" in midlife. Population studies suggest persistence into the 4thβ6th decade for most patients; remission is not the rule. Third: that biologics are a last resort. Modern guideline thinking has shifted toward earlier biologic initiation for moderate disease to prevent tunnel formation and permanent scarring, which are largely irreversible once established Alikhan 2019b.
audience
Population variability. Sex ratio in North American and European cohorts is ~3:1 female-to-male, reaching ~4:1 in some US datasets; East Asian (South Korea, Japan) cohorts show male predominance Garg 2017. African-American patients in US data carry the highest prevalence (~296 per 100,000 vs ~98 per 100,000 overall) Garg 2017. Onset peaks in the late teens through 30s; pediatric and post-menopausal onset both occur but are less common. Pregnancy: roughly one-third of patients improve, one-third worsen, one-third unchanged; postpartum often sees flare. Men: less prevalent overall but more likely to have genital/perineal involvement and severe (Hurley III) disease at presentation.
alternatives
Lifestyle adjuncts with reasonable evidence: smoking cessation (every guideline lists it; magnitude of HS-specific benefit is hard to quantify from observational data but the directional signal is consistent) Tzellos 2015; weight loss in patients with elevated BMI (bariatric studies show β₯15% weight loss β significant HS-severity improvement); zinc gluconate 90 mg/day (modest evidence, low-risk adjunct); dietary trials (low glycaemic / dairy elimination) with case-series-level evidence only. Hormonal options in women: spironolactone, OCP, finasteride, metformin β all guideline-listed as second-line options based on retrospective and small prospective data Alikhan 2019b. Older systemic agents pushed aside by biologics: isotretinoin (poor efficacy in HS β different from acne), oral retinoids (acitretin, modest), cyclosporin (some response in refractory cases), dapsone. Investigational pipeline: JAK inhibitors (upadacitinib, povorcitinib), IL-1 axis inhibitors, complement-pathway agents β Phase 2 and Phase 3 readouts ongoing.
failure-modes
The dominant failure mode is the 7β10 year diagnostic delay itself β during which patients accumulate permanent sinus tracts and scarring that no medical therapy can later reverse Saunte 2015. Patients consult on average more than three different physicians (GPs, dermatologists, surgeons, gynaecologists) and accumulate more than three misdiagnoses before correct attribution; longer delay correlates with worse Hurley stage and more comorbidities at diagnosis. Second failure mode: repeated incision-and-drainage of recurrent abscesses without instituting disease-modifying therapy β temporary relief, no change in trajectory, accumulating scar burden. Third: under-dosing or premature discontinuation of biologics β HS biologic doses are higher than the psoriasis labels (adalimumab 40 mg weekly, not every-other-week) and response is often slower (assessed at week 12β16); patients and clinicians who calibrate to psoriasis expectations stop too early. Fourth: ignoring comorbidity screening β HS patients have substantially elevated cardiovascular event and mortality risk (Egeberg's Danish cohort: HR 1.57 for MI, 1.33 for ischaemic stroke, 1.95 for CV death, 1.35 for all-cause mortality) Egeberg 2016 and the depression/suicidality burden is severe; treating only the skin misses the systemic-disease frame.
practicalities
Specialist access is the rate-limiting reality. The diagnosis is made by a dermatologist (often an HS-specialty clinic in academic centres); generalist mis-recognition is the headline reason for the diagnostic delay. Biologics are administered as subcutaneous injections at home after training. Cost without insurance is prohibitive: adalimumab US list price ~$70,000/year (biosimilars now available, ~30β50% lower), secukinumab and bimekizumab in similar tier. With US commercial insurance plus manufacturer copay assistance, out-of-pocket can drop to under $10/month for eligible patients; Medicare/Medicaid coverage variable and step-therapy requirements common (typically fail conventional therapy first). Outside the US, single-payer systems generally cover after failure of conventional therapy. Monitoring labs: TB screening (interferon-gamma release assay) before initiation, hepatitis serology, periodic CBC and liver panels.
stakes
Untreated or undertreated HS over 7β10 years of diagnostic delay tends to one trajectory: progression from isolated tender nodules in Hurley I, to recurrent abscesses and developing sinus tracts in Hurley II, to confluent draining tunnels and disfiguring scarring in Hurley III Sabat 2020. Once tunnels epithelialise they are permanent β medical therapy quiets inflammation around them but does not collapse the tunnel, which is why early intervention matters disproportionately. Quality-of-life impact ranks among the highest of any skin disease β pain is the most-reported symptom (mean NRS ~4, max-week NRS often 7β10 during flares) and correlates strongly with reduced QoL on Skindex-16 and DLQI scales. Depression prevalence ~21% (vs ~8% general population, OR 2.06), anxiety ~19% (OR 1.91), and suicide OR ~1.56 in meta-analytic data; the depression burden scales with Hurley stage (~35% in Hurley III) Machado 2019 Patel 2020 Phan 2020. Cardiovascular and metabolic comorbidity is substantial and reflects shared inflammatory drivers plus shared risk factors (smoking, obesity, insulin resistance): elevated risk of MI, stroke, cardiovascular death, and all-cause mortality in large registry data Egeberg 2016 Tzellos 2015.
payoff
Modern biologic therapy changes the trajectory measurably. With adalimumab, ~42β59% of patients achieve HiSCR (β₯50% reduction in inflammatory lesion count) by week 12 Kimball 2016; with secukinumab Q2W, similar ~42β45% HiSCR at week 16 sustained through week 52 Kimball 2023; with bimekizumab, HiSCR50 ~48β52% and HiSCR75 ~32β34% at week 16, sustained to week 48 Kimball 2024. Pain β the symptom most tied to QoL β improves substantially across biologic classes; in BE HEARD, the majority of patients rated skin pain as "much better" by week 48 and the proportion rating their pain as "severe" dropped from ~30% at baseline to ~5%. Onset of meaningful response is weeks-to-months, not days; the durability question (5- to 10-year disease-modification) is being answered in open-label extensions and registries. Mental-health comorbidity may improve as inflammation and pain remit, but this is correlated rather than RCT-proven. Early treatment before tunnel formation is the strongest payoff lever and the one most lost to diagnostic delay.
out-of-scope
Adjacent topics this entry signposts but does not cover end-to-end: acne vulgaris (different folliculopilosebaceous disease, different management); pilonidal disease (overlapping anatomic distribution but distinct pathogenesis); Crohn's disease and IBD (genuine HS-IBD co-occurrence β share IL-23/Th17 biology); psoriasis (also TNF/IL-17 responsive; readers with HS may have additional psoriasis). Smoking cessation as a standalone substance; weight management and GLP-1 receptor agonists; dermatology access (general).
The credibility range
Optimist case. HS is now a treatable chronic inflammatory disease on the same medicinal footing as psoriasis or rheumatoid arthritis. Three FDA-approved biologic classes (TNF-Ξ±, IL-17A, IL-17A+F) all demonstrate replicated Phase 3 efficacy with rapid, durable responses and acceptable safety profiles Kimball 2016 Kimball 2023 Kimball 2024. The pathogenesis is mechanistically resolved (follicular occlusion β innate immune cascade β Th17 dominance), explaining why each biologic class works and predicting which next-generation agents (JAK inhibitors, IL-1 axis blockers) should work too. Treatment access via biosimilars and copay assistance has improved costs meaningfully in the past 5 years. The patient-side problem is no longer "no treatment exists" but "diagnostic delay and referral failure prevent patients from reaching treatment" β a solvable problem of clinician and patient awareness.
Skeptic case. HiSCR50 β the standard primary endpoint β is a modest bar: a 50% reduction in inflammatory lesions, not remission. Across all three biologic classes the placebo-adjusted response rate is ~15β25 percentage points, with absolute responder rates of ~40β60% β meaning ~40β60% of patients on the most modern, expensive therapies do not achieve even this modest endpoint at week 12β16. Long-term durability beyond 1β2 years is reported mostly from open-label extensions and registries; head-to-head biologic-vs-biologic data are absent. Surgery rates remain high even with biologics β tunnels do not resolve medically. Comorbidities (cardiovascular, mortality, mental health) are pulled from observational data with substantial confounding by smoking, obesity, and socioeconomic status; the causal contribution of HS-specific inflammation to MACE/mortality is plausible but not RCT-proven. Diagnostic delay has been documented for two decades without measurable improvement.
Author's call. The article lands optimist-leaning: the substantive change in the past decade β from "incurable disease no one understands" to "chronic immune disease with three FDA-approved biologic classes and a defined mechanistic frame" β is real and underweighted in lay coverage. The two honest qualifiers carried throughout: (1) ~40β60% of biologic recipients still fall short of HiSCR50 at primary-endpoint timepoints, so the framing is "treatable, not curable, and durably manageable for the majority"; (2) the diagnostic-delay problem dominates outcomes more than the treatment-efficacy gap. The reader's highest-leverage action is recognition and dermatology access, not picking the right biologic.
Stakeholder and incentive map
- Commercial. AbbVie (adalimumab/Humira and biosimilars β first-mover advantage, IP cliff passed, biosimilar competition active), Novartis (secukinumab/Cosentyx), UCB (bimekizumab/Bimzelx). All three sponsored their pivotal Phase 3 trials. Investigational-stage: AbbVie (upadacitinib JAK), Incyte (povorcitinib), Boehringer (spesolimab IL-36).
- Professional. US Hidradenitis Suppurativa Foundation (USCHSF), Canadian HSF, European HS Foundation (EHSF) β issue guidelines, run annual symposia, advocate for diagnostic recognition and access. Strongly aligned with patient interest; modestly industry-funded.
- Patient/community. Active advocacy organisations (HS Connect, HS Heroes, Hope for HS) push diagnostic recognition, insurance access, and research funding. Reddit r/Hidradenitis and similar forums are large (~50K subscribers) and surface the lived experience β delays, misdiagnoses, copay-assistance navigation, biologic-switching journeys β that complement formal literature.
- Counter / friction. Insurance step-therapy requirements (fail antibiotics first) delay biologic initiation. Primary-care under-recognition is the dominant friction. No serious skeptical or anti-biologic camp exists comparable to other disease areas β the controversy is essentially absent because the unmet need is so visible.
Population variability
- Sex. Female-to-male ~3:1 in Western cohorts (4:1 in some US datasets); male predominance in East Asian cohorts Garg 2017. Men have higher rates of severe (Hurley III) and genital/perineal disease at presentation.
- Race/ethnicity. US population data show ~3-fold higher prevalence in African-American patients vs white patients (296 vs ~95 per 100,000); biracial patients also elevated Garg 2017. Diagnostic delay is longer in non-white patients; access disparities documented.
- Age. Onset most commonly second to third decade (late teens to 30s); pediatric onset associated with higher familial loading and faster progression; post-menopausal onset less common and often milder.
- Pregnancy. Variable β roughly one-third improve, one-third worsen, one-third unchanged; postpartum flare common. Adalimumab is the preferred biologic in pregnancy when therapy needed.
- Smoking/BMI status. Strong modifiers β non-smokers and patients at lower BMI tend to milder disease and better treatment response; smoking-cessation and weight optimisation are guideline-strength adjuncts Tzellos 2015.
- Genetic loading. Familial HS (Ξ³-secretase mutations: NCSTN, PSEN1, PSENEN) accounts for ~5% of cases and tends to earlier, more severe, more widely distributed disease.
Knowledge gaps
- No head-to-head biologic RCTs. Treatment selection is currently driven by patient factors (pregnancy, IBD history, prior response) rather than comparative efficacy data.
- Long-term (5β10 year) outcomes of early biologic intervention vs delayed initiation: does early biologic therapy in Hurley IβII disease prevent progression to tunnel-burdened Hurley III? Mechanistically expected; not RCT-proven.
- Causal contribution of HS-specific inflammation to cardiovascular mortality, independent of shared risk factors (smoking, obesity). Whether biologic therapy reduces MACE in HS is an open question; downstream from PIONEER inflammation-marker analyses but not endpoint-tested.
- Mechanistic role of the cutaneous microbiome and whether targeted microbiome interventions add to immune-blockade therapy.
- Why women in the West are 3β4Γ more affected but East Asian cohorts show male predominance β hormonal, genetic, and ascertainment-bias explanations all live.
- Diagnostic-delay interventions that work at scale. The problem has been documented for 20+ years without measurable improvement; primary-care education, patient-facing recognition tools, and AI-assisted dermatology triage are all unproven.
- Predictors of biologic response. ~40β60% of patients fall short of HiSCR50 on every approved biologic; no validated biomarker selects responders prospectively.
Scope vs brief. The brief named recurrent painful nodules, scarring, sinus tracts, mental health, diagnostic delay, and modern medical and biologic treatments. All six are covered end-to-end. No narrowing.
Action and cadence calls. Picked decide over know because the entry's payoff is reaching a dermatologist and choosing a treatment path β not just recognition. Picked as-needed cadence because the reader's action is trigger-based on symptom recognition; once on therapy, the cadence is daily/weekly, but that's the treatment's cadence, not the entry's.
Contraindications token left empty. The entry's recommendation is "see a dermatologist and decide on treatment with them," which is safe for every reader. Biologic-specific contraindications (advanced heart failure for anti-TNF, active IBD for anti-IL-17, pregnancy nuances) live in the contraindications section's warning callout and are the clinician's call; flagging the entry itself as unsafe for those groups would mislead.
Audience left unscoped. Female-to-male prevalence is ~3:1 in Western cohorts and the temptation was to scope audience.gender to female. Did not, because men with HS often present with more severe Hurley III and genital/perineal disease, and recognition equally matters for them. Onset peaks 18β39 but the disease persists through 40β59 in most patients, so age scoping would have mis-narrowed too.
Rating difficulties.
cost_burden: tension between $50β70K U.S. list and sub-$100/month real out-of-pocket for many insured patients. Landed at 4 (major) as the honest middle; without coverage the score would be 5.longevity: registry data show large hazard ratios for MI, CV death, all-cause mortality (Egeberg 2016) but treatment-effect on hard endpoints is not RCT-proven. Score 3 reflects "meaningful, mechanistically expected, not yet endpoint-tested."evidence: held at 4 rather than 5 because three Phase 3 programmes are strong but no head-to-head trials exist and HiSCR50 responder rates are 40β60% (modest by inflammatory-skin-disease standards).
Future-link candidates (to wire in once they exist): smoking cessation as a standalone entry; GLP-1 receptor agonists (semaglutide, tirzepatide) and weight management; inflammatory bowel disease; dermatology access. The out-of-scope section signposts these but does not anchor them.
Separate-entry candidates. None flagged inside HS. The adjacent topics above are independent entries in their own right, not branches of this one.
Hidradenitis Suppurativa
Untreated HS leaves permanent tunnels and scarring no later treatment can erase. Early diagnosis decides how your skin looks decades from now.
HS pain sits at the top of any skin-disease pain scale. Effective treatment moves it from severe to barely-there within months β usually the biggest single quality-of-life lift available.
Roughly one in five people with HS lives with clinical depression and suicide risk is elevated. Recognition and effective treatment lift both the skin disease and the mental-health load.
Active HS means painful boils and drainage in armpits, groin and other folds. Modern injectable treatments cut the lesion count substantially within a few months.
A subcutaneous injection at home every one to four weeks, plus periodic blood tests and wound care during flares.
Three injectable medicines approved by US regulators since 2015, each backed by large randomized trials. Response rates run around 40β60%, and no head-to-head trials yet β strong evidence, short of definitive.
HS isn't just skin. Heart attack and cardiovascular death rates are sharply elevated; treating the inflammation likely matters for what comes later.
Chronic pain and systemic inflammation are an energy tax you don't fully notice until they lift. People in remission talk about getting their afternoons back.
Lesions in armpits, groin and inframammary skin make every sleep position painful. Effective treatment restores sleep continuity within weeks of pain remission.
Severe chronic pain steals cognitive bandwidth. Pain remission gives some of it back.
Modern HS injectable medicines list at $50,000β$70,000 a year. US insurance plus manufacturer copay programs usually drop out-of-pocket under $100 a month for eligible patients; without coverage, pricing is brutal.